FY2024 EPS Estimates for Teladoc Health Increased by Analyst

Teladoc Health, Inc. (NYSE:TDOC) – Equities researchers at Zacks Research lifted their FY2024 earnings per share (EPS) estimates for shares of Teladoc Health in a research note issued on Wednesday, November 13th. Zacks Research analyst R. Department now anticipates that the health services provider will post earnings per share of ($1.15) for the year, up from their previous forecast of ($1.31). The consensus estimate for Teladoc Health’s current full-year earnings is ($1.17) per share. Zacks Research also issued estimates for Teladoc Health’s Q4 2024 earnings at ($0.19) EPS, Q1 2025 earnings at ($0.38) EPS, Q2 2025 earnings at ($0.28) EPS, Q3 2025 earnings at ($0.27) EPS, Q4 2025 earnings at ($0.12) EPS, FY2025 earnings at ($1.05) EPS, Q1 2026 earnings at ($0.37) EPS, Q2 2026 earnings at ($0.22) EPS, Q3 2026 earnings at ($0.21) EPS and FY2026 earnings at ($0.89) EPS.

Teladoc Health (NYSE:TDOC) last released its earnings results on Wednesday, October 30th. The health services provider reported ($0.19) EPS for the quarter, beating analysts’ consensus estimates of ($0.29) by $0.10. Teladoc Health had a negative return on equity of 10.06% and a negative net margin of 37.91%. The company had revenue of $640.51 million during the quarter, compared to the consensus estimate of $630.50 million.

A number of other research firms also recently issued reports on TDOC. Deutsche Bank Aktiengesellschaft lifted their price target on shares of Teladoc Health from $10.00 to $12.00 and gave the company a “hold” rating in a research report on Friday, November 1st. Jefferies Financial Group lifted their price objective on Teladoc Health from $8.00 to $10.00 and gave the stock a “hold” rating in a report on Tuesday, September 17th. Evercore ISI upped their target price on Teladoc Health from $8.00 to $9.00 and gave the company an “in-line” rating in a report on Tuesday, October 8th. TD Cowen cut their price target on Teladoc Health from $9.00 to $8.00 and set a “hold” rating for the company in a research note on Thursday, October 31st. Finally, DA Davidson lowered their price objective on shares of Teladoc Health from $12.00 to $8.00 and set a “neutral” rating on the stock in a research note on Thursday, August 1st. Fourteen investment analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average price target of $12.08.

Teladoc Health Stock Down 1.3 %

TDOC stock opened at $8.93 on Monday. The company has a current ratio of 1.73, a quick ratio of 1.69 and a debt-to-equity ratio of 0.66. The company’s 50-day moving average price is $8.96 and its 200 day moving average price is $9.31. Teladoc Health has a 52 week low of $6.76 and a 52 week high of $22.54. The company has a market cap of $1.54 billion, a P/E ratio of -1.55 and a beta of 0.90.

Institutional Investors Weigh In On Teladoc Health

Several institutional investors have recently bought and sold shares of TDOC. TCW Group Inc. acquired a new position in shares of Teladoc Health during the 3rd quarter valued at $2,464,000. Geode Capital Management LLC raised its position in Teladoc Health by 1.5% in the third quarter. Geode Capital Management LLC now owns 3,925,167 shares of the health services provider’s stock valued at $36,042,000 after purchasing an additional 56,864 shares during the period. Y Intercept Hong Kong Ltd acquired a new position in shares of Teladoc Health during the third quarter worth about $152,000. Quantinno Capital Management LP boosted its position in shares of Teladoc Health by 190.4% in the third quarter. Quantinno Capital Management LP now owns 186,143 shares of the health services provider’s stock worth $1,709,000 after buying an additional 122,050 shares during the period. Finally, Point72 Asset Management L.P. grew its stake in shares of Teladoc Health by 57.8% in the third quarter. Point72 Asset Management L.P. now owns 8,366,295 shares of the health services provider’s stock valued at $76,803,000 after buying an additional 3,063,172 shares in the last quarter. 76.82% of the stock is currently owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other news, Director Thomas Mckinley acquired 4,000 shares of Teladoc Health stock in a transaction dated Thursday, September 12th. The shares were acquired at an average cost of $7.69 per share, with a total value of $30,760.00. Following the purchase, the director now directly owns 39,077 shares of the company’s stock, valued at approximately $300,502.13. This trade represents a 11.40 % increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, CFO Mala Murthy sold 8,750 shares of the stock in a transaction that occurred on Tuesday, September 3rd. The stock was sold at an average price of $7.16, for a total transaction of $62,650.00. Following the sale, the chief financial officer now directly owns 85,767 shares of the company’s stock, valued at approximately $614,091.72. This trade represents a 9.26 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 20,051 shares of company stock valued at $143,565. Insiders own 0.95% of the company’s stock.

Teladoc Health Company Profile

Teladoc Health, Inc provides virtual healthcare services worldwide. The company operates through Teladoc Health Integrated Care and BetterHelp segments. The Integrated Care segment offers virtual medical services, including general medical, expert medical, specialty medical, chronic condition management, and mental health, as well as enabling technologies and enterprise telehealth solutions for hospitals and health systems.